Revolution Medicines RVMD
NASDAQ RVMD
$178.12 -21.58 (-10.81%)
As of: Nov 5, 2026 · 3:59 PM EST

Revolution Medicines (RVMD) Amortization - Intangibles (2025)

Updated

Revolution Medicines' Amortization - Intangibles was $300,000 in Q2 2025.

Analysis

Revolution Medicines (RVMD) Amortization - Intangibles (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,221.09 Bn 1,194.71 Bn 20.46 Bn
2 Johnson & Johnson 656.38 Bn 576.24 Bn 17.30 Bn
3 AbbVie 510.79 Bn 478.80 Bn 13.12 Bn
4 Merck 363.00 Bn 317.38 Bn 12.21 Bn
5 Novartis Ag 313.89 Bn 287.12 Bn -
6 Astrazeneca 290.02 Bn 263.91 Bn 13.26 Bn
7 Amgen 249.59 Bn 204.98 Bn 7.24 Bn
8 Gilead Sciences 208.15 Bn 183.26 Bn 6.73 Bn
9 Pfizer 170.74 Bn 118.10 Bn 12.56 Bn
10 Revolution Medicines 38.00 Bn 28.20 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 300,000.00
API Access

Revolution Medicines Amortization - Intangibles API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=amortization-intangibles&ticker=RVMD&period=max&api_key=YOUR_API_KEY